Previous randomized trials have demonstrated that intensive insulin therapy significantly reduces the risk of both microvascular and macrovascular complications, underscoring the importance of early and rigorous glycemic control in improving long-term outcomes among individuals with T2D [6,7,8]. The gene discussed is INS; the disease is type 2 diabetes mellitus.